SLXN 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-14

• We are a clinical-stage biotechnology company developing, through our subsidiaries, RNA interference (RNAi) therapies for cancers driven by mutations in the Kirsten rat sarcoma viral oncogene homolog (“KRAS”). Our approach targets a significant unmet medical need, as treatment innovation for KRAS-dr…

• During the second quarter of 2026, we received formal regulatory approvals— from the Israeli Ministry of Health (the “Israeli MoH”) and Germany's Federal Institute for Drugs and Medical Devices (“BfArM”) (in the case of BfArM, based on the positive opinion of the Ethics Committee of the North Rhine …

• As a clinical stage company, we have not realized any revenues to date, and have been solely reliant on financing transactions to fund our operations.

• Prior to the Business Combination, as a private company, we financed our operations primarily with the net proceeds from private offerings of our ordinary shares and convertible preferred shares, convertible financing agreements, and Simple Agreement for Future Equity (SAFE) financings, as well as r…

• Initially as a public company, at the time of the Closing of the Business Combination, we raised $2.0 million via a private investment in public entity (PIPE) financing, in which Moringa sold to Greenstar, LP, an affiliate of the Moringa sponsor, 148 newly issued Moringa ordinary shares at a price o…

相对上期删除的文字 · 来源:10-Q · 2026-05-15

• We are a Cayman Islands exempted company that was originally formed for the purpose of effectuating the Business Combination and that now serves as a publicly traded holding company for each of Silexion Israel (through which our operations are carried out) and Moringa (which has no operations and wh…

• We conduct our operations primarily through our principal subsidiary, Silexion Israel, a clinical-stage biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the Kirsten rat sarcoma viral oncogene homolog (“KRAS”). The KRAS gene, …

• Our proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while main…

• To address both localized and systemic disease, as well as the tumor’s dense desmoplastic stroma, which limits the effectiveness of current treatments, our novel delivery approach, which we refer to as an Integrated Treatment Regimen, involves administering SIL204 both directly into the tumor and sy…

• As a clinical stage company, we have not realized any revenues to date. Prior to the Business Combination, we financed our operations primarily with the net proceeds from private offerings of our ordinary shares and convertible preferred shares, convertible financing agreements, and Simple Agreement…